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AbstrACt
Objectives To describe the use of drug-eluting stents 
(DESs) in the largest population of statutory health 
insurance members in Germany, including newly 
developed bio-resorbable vascular scaffolds (BVSs), and 
to evaluate 1-year complication rates of DES as compared 
with bare metal stents (BMSs) in this cohort.
Design Routine data analysis of statutory health 
insurance claims data from the years 2008 to 2014.
setting The German healthcare insurance Allgemeine 
Ortskrankenkasse covers approximately 30% of the 
German population and is the largest nationwide provider 
of statutory healthcare insurance in Germany.
Participants and interventions We included all patients 
with a claims record for a percutaneous coronary 
intervention (PCI) with either DES or BMS and additionally, 
from 2013, BVS. Patients with acute myocardial infarction 
(AMI) were excluded. Main outcome measure: major 
adverse cerebrovascular and cardiovascular event 
(MACCE, defined as mortality, AMI, stroke and transient 
ischaemic attack), bypass surgery, PCI and coronary 
angiography) at 1 year after the intervention.
results A total of 243 581 PCI cases were included 
(DES excluding BVS: 143 765; BVS: 1440; BMS: 98 376). 
The 1-year MACCE rate was 7.42% in the DES subgroup 
excluding BVS and 11.29% in the BMS subgroup. The 
adjusted OR for MACCE was 0.72 (95% CI 0.70 to 0.75) 
in patients with DES excluding BVS as compared with 
patients with BMS. In the BVS group, the proportion of 
1-year MACCE was 5.0%.
Conclusion The analyses demonstrate a lower MACCE 
rate for PCI with DES. BVSs are used in clinical routine 
in selected cases and seem to provide a high degree of 
safety, but data are still sparse.
IntrODuCtIOn
Percutaneous coronary interventions (PCIs) 
are a commonly and increasingly used revas-
cularisation strategy in patients with coronary 
artery disease (CAD). In Germany, 361 377 
PCIs were performed in 2014.1 Germany is a 
model region with respect to early availability 
of new treatment options. For example, 
the mean time from approval to market for 
new medical drugs is 3.5 months compared 
with 5.8 months in the Netherlands and 16 
months in Spain.2
In recent years, case numbers for PCI have 
been stable on a high level. Still, the utilisa-
tion pattern of PCI has changed dramatically 
over time with a distinct increase of PCIs 
in patients over the age of 70 years and in 
patients with comorbidities like diabetes 
mellitus and chronic kidney disease, as 
strengths and limitations of this study
 ► Data of the largest provider of statutory healthcare 
insurance in Germany were used, which covers 
around 30% of the German population (24 million 
people).
 ► A total of 243 581 percutaneous coronary 
intervention  (PCI) cases were included, and time 
trends in PCI utilisation over a 7-year time period 
were analysed. Data on newly developed BVS are 
also presented.
 ► Major adverse cerebrovascular  and cardiovascular 
event, bypass surgery, PCI and coronary angiography 
within 1 year after the intervention were analysed.
 ► Multivariable logistic regression models were used 
to evaluate the association of PCI treatment (drug-
eluting stent excluding bio-resorbable vascular 
scaffold, bare metal stent) on outcome.
 ► A subgroup analysis according to the pharmaceutical 
drug and carrier material was performed.
 ► The external validity of the data on PCI utilisation is 
limited due to slight differences between Allgemeine 
Ortskrankenkasse insurance members and German 
patients overall with regard to age and comorbidity 
profile.
 ► Data were generated as routine data for billing of 
claims. Thus, coding inaccuracies cannot be ruled 
out and important variables may be missing. For 
example, it was not possible to assess whether a 
repeat revascularisation was performed in the same 
vessel as the index PCI.
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compared with 2008.1 Additionally, materials used in PCIs 
have changed. While in the early years uncoated stents 
made of differing metal alloys (bare metal stents (BMSs)) 
were used, stents coated with pharmaceutical drugs and 
polymer (drug-eluting stents (DESs)) are on the rise. 
DESs were developed to prevent scarring and restenosis 
of the treated coronary vessel by releasing active agents 
over a defined period of time. Drugs commonly used in 
these stents inhibit cell growth, for example, immunosup-
pressant drugs like Everolimus, Zotarolimus, Sirolimus 
or the cytostatic drug Paclitaxel—although Paclitaxel is 
used increasingly less—all in combination with different 
carrier materials (polymer). The latest development 
involves bio-resorbable vascular scaffolds (BVSs), which 
support the vessel over a certain period of time after 
which they dissolve. The safety and efficacy of BVS have 
been challenged recently.3
DESs have led to a significant reduction of in-stent 
restenoses (ISR).4–7 Still, particularly in the days of 
first-generation DES in the mid-2000s, there were consid-
erable safety concerns, as a number of studies reported 
increased rates of late in-stent thromboses compared with 
BMS.8–12 This argument is still being used to favour BMS. 
For the second-generation DES, these concerns seem 
not to apply13 and current guidelines recommend DES 
for most patients, although very recent data show that 
BMS may still have their place (eg, patients with recent 
bleeding or a need for concomitant anticoagulation 
therapy).14 15 The European Society of Cardiology guide-
lines mention BVS as a ‘promising’ option without a clear 
recommendation.15 A recent meta-analysis on the use of 
the ‘ABSORB’ stent, which is the momentarily most used 
BVS, resulted in the conclusion that BVS had increased 
definite/probable scaffold thrombosis (ST)and myocar-
dial infarction (MI) during follow-up compared with 
DES.16
This analysis of German statutory health insurance 
claims data was performed on the basis of changing 
conditions and patient populations for PCI treatment, to 
assess the clinical routine of coronary revascularisation 
with PCI in Germany. Up until now, the only publica-
tion from Germany uses data from the German DES 
Registry, in which 98 hospitals participated.17 We aimed 
to test the following hypotheses: (a) DESs are the new 
clinical standard for PCI in Germany and (b) DESs are 
effective and safe with respect to repeat revascularisation 
and major adverse cerebrovascular and cardiovascular 
events (MACCEs) within 1 year after the initial PCI and 
(c) BVSs are increasingly used in clinical routine with a 
safe outcome.
MethODs
Nationwide, anonymous billing data of the statutory 
health insurance company Allgemeine Ortskranken-
kasse (AOK) were used for all 24 million AOK-insured 
persons in Germany. AOK provides healthcare insurance 
for approximately 30% of the German population and is 
the largest nationwide provider of statutory healthcare 
insurance in Germany. Every person is allowed to enrol 
with AOK regardless of age, comorbidity, income or type 
of employment. Data were derived from billing data for 
inpatient hospital treatment. They comprise a unique 
identification number, age, sex, principal diagnosis and 
other diagnoses, procedures, length of stay, patient survival 
and insurance status. Diagnoses were coded according 
to the 10th revision of the International Classification 
of Diseases (ICD-10).18 Procedures were documented 
using the German version of the International Classifica-
tion of Procedures in Medicine,19 the ‘Operationen- und 
Prozedurenschlüssel’ (OPS). Healthcare providers and 
healthcare insurances jointly issue binding guidelines for 
coding of diagnoses and procedures in hospital claims.20 
Hospital claims data in Germany are thoroughly checked 
against these guidelines and for plausibility by the medical 
review board of the Social Health Insurance Funds and 
are returned to hospitals for correction if necessary. 
Corrections are included in the claims data used in this 
analysis.
We included all AOK cases from 2008 to 2014 with a 
claim for inpatient treatment with DES or BMS. Cases were 
identified by OPS codes (DES excluding BVS: 8–837 .m; 
BVS: 8-83d.0; BMS: 8–837 .k). The hospitalisation during 
which this PCI was performed is referred to as the index 
hospitalisation.
We excluded all cases with acute myocardial infarction 
(AMI) and patients with an age below 20 years as well as 
patients with cardiac surgery or PCI in the year before the 
index hospitalisation, independent of whether the latter 
was performed as an inpatient or outpatient treatment, as 
the outcome of these patients is strongly dependent on 
other factors than the type of stent.
For the analysis, we formed three subgroups: patients 
with DES excluding BVS, patients with BVS and patients 
with BMS treatment. Data for BVS were available only for 
the years 2013 and 2014.
If patients had multiple stenting during the index 
hospitalisation with combined DES and BMS stenting, 
they were assigned to the DES group. This applies to 
n=5.986 (2.46%) of cases.
First, we performed a descriptive analysis on the devel-
opment of BMS and DES treatment over the predefined 
5-year period. Cochrane-Armitage Trend Test was used 
to analyse trends over these years. In the DES group, 
we analysed subgroups according to the pharmaceutical 
drug and carrier material as indicated within the OPS 
code 8-83b. We then analysed events during the 1-year 
follow-up period for the DES and BMS subgroups. Primary 
endpoint was the 1-year MACCE rate (mortality, AMI, 
stroke or transient ischaemic attack (TIA); ICD10: I21, 
I22, I63, G45), which is the proportion of patients who 
had one or more of these events during the follow-up year. 
These events are not ordered hierarchically, that is, the 
MACCE rate is the proportion of patients who had at least 
one of these events within the follow-up year. In addition, 
we assessed coronary artery bypass graft CABG surgery 
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(OPS: 5–361, 5–362, 5–363), PCI (OPS: 8–837, 8-83d) 
and coronary angiographies (OPS: 1–275) for different 
time frames within the 1-year follow-up period. To eval-
uate the association of PCI treatment (DES excluding 
BVS versus BMS) with outcomes, we used multivariable 
logistic regression models. Adjustment was made for age, 
sex, comorbidities according to the Elixhauser classifica-
tion,21 shock, New York Heart Association (NYHA) class 
(I versus II, III or IV), left main CAD, multivessel disease 
(two or three vessels), number of PCIs (one coronary 
artery versus a minimum of two) at index hospitalisa-
tion, AMI and dialysis in the year preceding admission 
and year of treatment. Comorbidities were defined using 
the Elixhauser classification. The definition includes 
31 acute and chronic comorbidities: congestive heart 
failure, cardiac arrhythmias, valvular disease, pulmo-
nary circulation disorders, peripheral vascular disease, 
uncomplicated hypertension, complicated hypertension, 
uncomplicated diabetes, complicated diabetes (ie, coma, 
ketoacidosis, vascular disease), renal failure, liver disease, 
coagulopathy, blood loss anaemia, deficiency anaemia, 
hypothyroidism, peptic ulcer disease excluding bleeding, 
chronic obstructive pulmonary disease (COPD), obesity 
(BMI ≥30 kg/m²), weight loss, solid tumour without 
metastasis, metastatic cancer, lymphoma, fluid and elec-
trolyte disorders, rheumatoid arthritis/collagen vascular 
diseases, paralysis, other neurological disorders, alcohol 
abuse, drug abuse, psychoses, depression and AIDS/HIV. 
Comorbidities were identified using the coding algorithm 
by Quan et al based on the ICD-10 coding.22 AMI, cardio-
genic shock, NYHA class (I versus II, III or IV), left main 
CAD, multivessel disease (two or three vessels), which 
are not included in the Elixhauser classification, were 
also included because they are potential risk factors and 
differ between the analysed groups (p<0.005). All comor-
bidities were entered as separate dichotomous variables. 
Age was used as a continuous variable in the regression 
analysis. Patients whose AOK insurance ended before 
the end of the 1-year follow-up period were censored, 
resulting in differing case numbers for different follow-up 
periods. All analyses were performed using STATA V.11.2 
(StataCorp).
ethics
The present study is based on data provided by hospitals 
for health insurance accounting. The recommendations 
for good practice in secondary data analysis developed by 
the German Working Group on the Collection and Use of 
Secondary Data23 were applied in full. This type of anal-
ysis requires no formal ethics committee approval.
results
The analysis included 243 581 cases with PCI, 143 765 
(59.02%) in the DES group excluding BVS, 1440 (0.59%) 
in the BVS group and 98 376 (40.39%) in the BMS group. 
In total, 37.0% of all eligible cases (n=659 067) with PCI 
were included. Cases were excluded according to the 
exclusion criteria (AMI at the index hospitalisation, 
cardiac surgery or PCI in the year before the index hospi-
talisation or age below 20 years).
study population
Table 1 shows the basic characteristics of our study popu-
lation. There were significant differences in patient 
characteristics between groups (patient age: p<0.001, 
median test; other variables: p<0.05; χ2 test) in all vari-
ables except coronary two-vessel disease (p=0.408; χ2 test) 
and obesity (p=0.054; χ2 test). Patients in the DES group 
excluding BVS were 2 years younger than patients in the 
BMS group (median: 70 vs 72 years). The proportions of 
patients with prior MI, coronary three-vessel disease, left 
main CAD and diabetes were higher in the DES group 
excluding BVS as was the proportion of patients with 
multiple stenting (number of PCIs >1; DES: 18.5% vs BMS: 
6.3%). In the BMS group, the proportions of patients with 
heart failure, NYHA class >1, cardiac arrhythmia, valvular 
disease and COPD were higher. The median age of the 
BVS group was 64 years, and the proportion of patients 
with concomitant diseases was lower than in the other 
groups.
The age of patients increased in all groups over time 
but more prominently in the BMS group (median age 
in years: DES group excluding BVS 2008: 68; 2014: 71; 
BMS group 2008: 70; 2014: 75). In 2014, the propor-
tion of patients with an age above 70 years was 53.80% 
in the DES group excluding BVS, 69.60% in the BMS 
group and 35.96% in the BVS group. Likewise, the 
proportion of comorbidities increased over time. This 
was also most prominent in patients of the BMS group 
with heart failure, cardiac arrhythmia, valvular diseases 
and chronic kidney disease. The proportion of patients 
with cardiac arrhythmia, for example, increased by 8.5% 
(2008: 16.0%; 2014: 24.5%) in the DES group excluding 
BVS and by 28.2% (2008: 24.3%; 2014: 52. 5%) in the 
BMS group.
time trends in percutaneous coronary interventions
Figure 1 shows the frequency of PCI treatment in AOK 
patients over time. The proportion of DES increased from 
33.6% in 2008 (n=10 843) to 84.2% in 2014 (n=30 181), 
including 2.3% BVS in 2014 (n=856). The proportion of 
BMS decreased accordingly.
Figure 2 shows the development of DES treatment over 
the predefined 7-year period according to pharmaceu-
tical drug and carrier materials used. The proportion 
of Everolimus-eluting stents with polymer increased 
markedly (2008: 25.5%; 2014: 46.4%). The same is true 
for the proportion of Zotarolimus-eluting and Biolim-
us-eluting stents with polymer (2008: 17.7%; 2014: 25.5% 
and 2008: 5.8%; 2014: 12.4%, respectively). The use of 
all other stents decreased over this time period, most 
prominently Paclitaxel-eluting stents with polymer 
(2008: 29.7%; 2014: 1.5%). Very rarely used stents with 
case numbers below 100 over the 5-year period are not 
shown. Drugs used in BVS are not sufficiently coded in 
the data set.
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MACCe and repeat revascularisation within 1 year
Table 2 shows event rates for the DES group excluding 
BVS and BMS group over the whole study period and 
for the respective years of the study period. In total, the 
proportion of MACCE during the 1-year period after the 
index PCI was 7.4% in the DES group excluding BVS and 
11.3% in the BMS group. Repeat coronary procedures 
occurred more frequently in the DES group excluding 
BVS. The proportion of repeat coronary angiographies, 
for example, was 3.4% higher in the DES group excluding 
BVS (34.5% as compared with 31.1% in the BMS group). 
In the BVS group (data available only for 2013 and 2014), 
the proportion of 1-year MACCE was 5.0% and the 
1-year mortality was 2.5%. Repeat coronary procedures 
within 1 year occurred more frequently in BVS patients 
(PCI: 25.8%; repeat coronary angiographies: 39.6%).
In the DES group excluding BVS, there was a small 
increase with respect to 1-year MACCE over time (p<0.001, 
trend test). One-year mortality increased (2008: 3.6%; 
2014: 5.1%; p<0.001), whereas the proportion of AMI 
Table 1 Patient characteristics, for all patients and for the subgroups of patients with DES excluding BVS, BMS and BVS
Total DES excluding BVS BMS BVS
Number (N) 243 581 143 765 98 376 1440
Age (median (IQR)) 71 (62–77) 70 (61–76) 72 (65–78) 64 (55–73)
Female patients (%) 32.23 31.52 33.31 28.47
Diagnoses at the index hospital stay (%)*
  Cardiovascular diseases
   Prior MI 9.60 10.34 8.55 7.50
   Stroke 0.48 0.40 0.59 0.28
   TIA 0.27 0.21 0.35 0.14
   Intracerebral bleeding 0.04 0.03 0.06 0.00
   Congestive heart failure 26.69 25.45 28.53 25.21
   NYHA stage >1 22.07 21.02 23.62 21.67
   Coronary two-vessel disease 31.54 31.63 31.39 32.15
   Coronary three-vessel disease 37.63 40.36 33.73 30.49
   Left main CAD 3.77 4.68 2.47 1.46
   Shock 0.55 0.49 0.64 0.14
   Arterial hypertension 78.63 79.52 77.34 77.92
   Cardiac arrhythmia 25.30 20.48 32.44 17.29
   Valvular disease 10.11 8.75 12.14 7.43
   Peripheral vascular disorders 11.56 11.25 12.06 8.06
  Other concomitant diseases
   Diabetes mellitus 33.51 35.22 31.07 28.75
   COPD 9.55 8.76 10.71 9.31
   CKD 19.48 18.70 20.73 12.15
   ESRD 3.92 3.91 3.97 2.26
   Hypothyroidism 7.22 7.54 6.71 9.44
   Obesity (BMI ≥30 kg/m²) 12.00 12.03 11.93 13.96
Interventions at index hospital stay (%)
  PCI > 1 coronary artery† 13.52 18.45 6.32 12.57
  Pacemaker 1.20 1.04 1.45 0.63
  ICD implantation 0.79 0.70 0.93 0.28
  Dialysis 1.75 1.59 2.00 0.69
*Other comorbidities according to Elixhauser et al with a frequency <5% are not shown (pulmonary circulation disorders, liver disease, blood 
loss anaemia, deficiency anaemia, peptic ulcer disease excluding bleeding, coagulopathy, weight loss, solid tumour without metastasis, 
metastatic cancer, lymphoma, rheumatoid arthritis/collagen, paralysis, other neurological disorders, alcohol abuse, drug abuse, psychoses, 
depression, AIDS/HIV).
†At least two stents in one or more coronary arteries during index hospitalisation.
BMS, bare metal stent; BVS, bio-resorbable vascular scaffold; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; 
DES, drug-eluting stent; ESRD, end-stage renal disease; ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NYHA, New 
York Heart Association; TIA, transient ischaemic attack.
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decreased slightly over time (2008: 2.5%; 2014: 2.2%; 
p=0.013). In the BMS group, the proportion of 1-year 
MACCE increased by 5.3% (2008: 9.6%; 2012: 14.9%; 
p<0.001). This is mostly driven by an increased mortality 
(2008: 5.3%; 2014: 10.8%; p<0.001).
Looking at repeat coronary procedures over time, data 
show a decrease, particularly of coronary angiographies, 
(DES excluding BVS: 2008: 40.81%, 2014: 30.69%; BMS: 
2008: 33.66%, 2014: 26.53%; p<0.001 for both) but also of 
CABG surgery (DES excluding BVS: 2008: 1.94%, 2014: 
0.90%; BMS: 2008: 2.15%, 2014: 1.28%, p<0001 for both).
Table 3 shows ORs for DES excluding BVS compared 
with BMS treatment, risk adjusted for patient character-
istics and year of treatment. After risk adjustment, the 
DES group excluding BVS had a lower risk for 1-year 
MACCE (OR=0.72; 95% CI 0.70 to 0.75) and particu-
larly for 1-year mortality (OR=0.70; CI 0.67 to 0.74), 
1-year CABG surgery (OR=0.69; CI 0.63 to 0.75) and 
repeat PCI within 91–365 days after the index PCI 
(OR=0.87; CI 0.81 to 0.93). DES group excluding BVS 
also had a higher risk of PCI within 90 days after the 
index PCI (OR=1.14; CI 1.07 to 1.21) and of repeat 
Figure 1 Frequency of drug-eluting stent (DES) and bare metal stent (BMS) including bio-resorbable vascular scaffold (BVS) 
utilisation over time (2008–2014).
Figure 2 Frequency of the different drug-eluting stent (DES) used over time (2008–2014) according to active drug component 
and carrier material (groups >1% only). Multiple selections were possible due to implantation of different stent types during 
index procedure. Bio-resorbable vascular scaffolds were not included. OPS ‘Operationen- und Prozedurenschlüssel’ (OPS) 
German version of the International Classification of Procedures in Medicine.19
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coronary angiography within 1 year (OR=1.14; CI 1.06 
to 1.23).
Like DES excluding BVS, ORs for BVS compared with 
BMS were lower for 1-year MACCE (OR=0.59; 95% CI 
0.46 to 0.74) and for 1-year mortality (OR=0.55; CI 0.41 
to 0.74). The BVS group also had a higher risk of PCI 
within 90 days after the index PCI (OR=1.83; CI 1.51 to 
2.22) and of repeat coronary angiography within 1 year 
(OR=1.64; CI 1.33 to 2.02).
Influence of Des stent type
Table 4 shows the comparison of newer versus first-gen-
eration (Paclitaxel) DES. Bio-resorbable stents were 
excluded as the respective code was only available for 
2013 and 2014.
DIsCussIOn
This study assesses the safety of DES in clinical routine in 
Germany within the first year after index PCI, using statu-
tory health insurance claims data from the largest health 
insurance in Germany, which covers around 30% of the 
German population. In addition, we analysed the conse-
quences of changes in DES utilisation over a 7-year time 
period. Our data show that the use of DES increased over 


















DES excluding BVS (n=143 765)
Mortality during index hospitalisation 0.57 0.41 0.42 0.50 0.44 0.56 0.60 0.83
MACCE (1 year) 7.42 7.04 7.60 7.21 7.01 7.17 7.53 8.28
  Mortality 4.22 3.59 3.53 3.94 3.88 4.07 4.43 5.10
  AMI 2.22 2.52 2.52 2.14 2.16 2.18 2.09 2.19
  Stroke 1.06 1.05 1.01 1.13 1.10 0.93 1.07 1.13
  TIA 0.55 0.50 0.44 0.61 0.48 0.60 0.60 0.55
CABG after index hospitalisation (1 year) 1.20 1.94 1.44 1.52 1.22 1.04 1.02 0.90
  Of these: within 30 days 0.09 0.11 0.08 0.11 0.10 0.11 0.09 0.08
  Of these: within 31–365 days 1.10 1.83 1.36 1.41 1.12 0.93 0.93 0.81
PCI after index hospitalisation (1 year) 21.40 22.50 22.86 22.46 21.80 21.09 20.65 20.32
  Of these: within 90 days 12.59 11.62 12.18 12.37 12.75 12.91 12.75 12.76
  Of these: within 91–365 days 8.52 10.68 10.44 9.83 8.79 7.90 7.55 7.20
Coronary angiography after index 
hospitalisation (1 year)
34.49 40.81 39.13 37.50 35.02 33.19 32.49 30.69
BMS (n=98 376)
Mortality during index hospitalisation 0.97 0.64 0.83 0.95 1.00 1.23 1.51 1.33
MACCE (1 year) 11.29 9.58 10.33 11.05 11.32 12.68 14.10 14.93
  Mortality 7.08 5.26 6.15 6.76 7.32 8.60 9.64 10.80
  AMI 3.33 3.44 3.26 3.38 3.19 3.20 3.47 3.35
  Stroke 1.44 1.36 1.26 1.42 1.47 1.51 1.75 1.72
  TIA 0.72 0.61 0.82 0.70 0.62 0.81 0.87 0.74
CABG after index hospitalisation (1 year) 1.70 2.15 1.97 1.66 1.39 1.28 1.40 1.25
  Of these: within 30 days 0.14 0.13 0.12 0.14 0.15 0.11 0.14 0.23
  Of these: within 31–365 days 1.56 2.01 1.84 1.51 1.24 1.16 1.25 1.00
PCI after index hospitalisation (1 year) 19.90 21.22 20.00 20.22 19.67 19.50 18.08 17.37
  Of these: within 90 days 10.17 10.55 10.02 10.28 10.42 10.28 9.44 8.99
  Of these: within 91–365 days 9.38 10.43 9.66 9.61 8.85 8.79 8.16 7.84
Coronary angiography after index 
hospitalisation (1 year)
31.14 33.66 32.21 31.84 30.26 28.71 28.29 26.53
Patients whose AOK insurance ended before the end of the 1-year follow-up period were censored, resulting in differing case numbers 
for different follow-up periods. AMI, acute myocardial infarction;  BMS, bare metal stent; BVS, bio-resorbable vascular scaffold; CABG, 
coronary artery bypass graft; DES drug-eluting stent; MACCE, major cerebrovascular and cardiovascular event; PCI, percutaneous coronary 
intervention; TIA, transient ischaemic attack.
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time. One-year MACCEs are consistently less frequent 
than with BMS over the whole observation period.
limitations
Our analyses included AOK patients only. Even though 
AOK patients form a large population of 24 million 
insured persons and represent around one-third of all 
inpatient hospital cases in Germany, external validity of 
our data on PCI utilisation and MACCE rates is limited 
due to the fact that the AOK-insured population differs in 
age and comorbidity profile when compared with other 
health insurance providers in Germany.24 Comparing 
AOK cases to all German patients with coronary angi-
ography and PCI in 2013, there are slight differences 
in our study population (female sex: 39.8% (AOK) vs 
35.4% (Germany); age ≥70 years: 52.7% (AOK) vs 51.8% 
(Germany)).25 However, these patient characteristics were 
controlled for in risk-adjusted analyses.
Table 3 Univariable and multivariable logistic regression analysis of the effect of PCI treatment—DES excluding BVS versus 





Mortality during index hospitalisation 0.70 (0.61 to 0.80) 0.59 (0.53 to 0.66)
MACCE (1 year) 0.72 (0.70 to 0.75) 0.63 (0.61 to 0.65)
  Of these: mortality (1 year) 0.70 (0.67 to 0.74) 0.58 (0.55 to 0.61)
CABG after index hospitalisation (1 year) 0.69 (0.63 to 0.75) 0.70 (0.65 to 0.76)
  Of these: within 30 days 0.60 (0.47 to 0.76) 0.68 (0.54 to 0.87)
  Of these: within 31–365 days 0.70 (0.64 to 0.77) 0.70 (0.65 to 0.77)
PCI after index hospitalisation (1 year) 0.99 (0.94 to 1.04) 1.11 (1.04 to 1.15)
  Of these: within 90 days 1.14 (1.07 to 1.21) 1.27 (1.20 to 1.35)
  Of these: within 91–365 days 0.87 (0.81 to 0.93) 0.90 (0.84 to 0.96)
Coronary angiography after index hospitalisation (1 year) 1.14 (1.06 to 1.23) 1.16 (1.09 to 1.25)
*Risk adjustment included age, sex, comorbidities according to the Elixhauser classification, shock, New York Heart Association class (I 
versus II, III or IV), left main CAD, multivessel disease (two or three vessels), number of PCI (one coronary artery versus a minimum of two) at 
index hospitalisation, AMI and dialysis in the year preceding admission and year of treatment. 
BMS, bare metal stent; BVS, bio-resorbable vascular scaffold; CABG, coronary artery bypass graft; DES, drug-eluting stent; MACCE, major 
cerebrovascular and cardiovascular event; PCI, percutaneous coronary intervention.
Table 4 Multivariable logistic regression analyses of the effect of DES type on event rates (claims data of the German local 
healthcare funds in 2008–2014)
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*Risk adjusted for age, sex, comorbidities according to Elixhauser classification, shock, New York Heart Association class (I versus II, III 
or IV), left main disease, multivessel disease (two or three vessels), number of PCI (one coronary artery versus a minimum of two) at index 
hospitalisation, AMI and dialysis in the year preceding admission. BVSs were not included.
BMS, bare metal stent; BVS, bio-resorbable vascular scaffold; CA, coronary angiography; CABG, coronary artery bypass graft; DES, drug-
eluting stent; MACCE, major cerebrovascular and cardiovascular event; PCI, percutaneous coronary intervention.
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Data were generated as routine data for billing of claims. 
Coding inaccuracies cannot be ruled out, and important 
variables may be missing. For example, we were unable to 
assess whether a repeat revascularisation was performed 
in the same vessel as the index PCI. We were also unable 
to differentiate restenoses and stent thromboses and 
therefore chose mortality, AMI and repeat coronary 
procedures as outcomes.
In addition, it has to be noted that due to missing 
present on admission indexing of AMI, stroke and TIA 
in claims data, these diagnoses cannot be included under 
MACCE during the index hospitalisation. The propor-
tion of these diagnoses after PCI has been reported at 
around 0.3%.25
Finally, routine data do not include detailed clinical 
information, for example, that needed to check whether 
indications conformed to the guidelines.
study population
Our data show a distinct change in patient characteristics 
over the study period from 2008 to 2014. The proportion 
of patients with an age above 70 years increased, as has 
been previously reported for PCI patients in Germany 
(German Heart Report: relative increase by 14.4% in men 
and 6.1% in women). The proportions of patients with 
diabetes and chronic kidney disease in our data were 34% 
and 19%, respectively (German Heart Report: 27% and 
23% in 2014).1 Patients in the BMS group were slightly 
older and had more comorbidities such as valvular 
diseases, atrial fibrillation and coagulopathies, indi-
cating a need for chronic anticoagulation or an increased 
tendency to bleed. For these patients, treatment seems 
to follow the current guideline recommendations.15 Our 
data show a significant increase of these comorbidities in 
the BMS group over time. In the DES group excluding 
BVS, the proportions of patients with multiple-vessel CAD, 
left main CAD, previous AMI and diabetes were higher. In 
addition, multiple stenting occurred more frequently in 
this group. These observations confirm study results and 
recommendations of medical societies on an advantage 
of DES in patients with an increased risk for restenosis 
or left main stenosis.26–28 BMS treatment is currently 
recommended for patients with an increased risk of stent 
thrombosis and in patients with expected complications 
regarding dual antiplatelet therapy (eg, due to planned 
elective surgery or anticipated compliance issues).27
time trends in percutaneous coronary interventions
While the utilisation of PCI has been stabilised on a high 
level over the past years, the proportion of DES doubled 
during the study period from 33.6% in the year 2008 to 
84.2% in 2014, and accordingly, the proportion of BMS 
was quartered during this period. Case numbers for 2014 
confirm a published proportion for Germany of 85.9% 
for DES,1 although these include patients with AMI. For 
2013, an increase of DES utilisation to 79% was reported.1 
In our analysis, immunosuppressive drugs with polymer 
cover 83.1% of DES in 2014 (Everolimus: 45.5%; Zotar-
olimus: 23.9%; Sirolimus: 8.7; Biolimus: 8.0%). The 
increase of DES can be explained by recent reports of 
clinical trials on their efficacy and safety.26 29 30
Nevertheless, in the Swedish SCAAR registry (DESs use 
data available until 2010), the DES rate was a little bit 
lower with 32% in the time frame 2009–2010 with same 
tendency of continuous increase except in 2007–2008 
when safety issues were intensively discussed worldwide.31
MACCe and repeat revascularisation within 1 year
The 1-year MACCE rate in our cohort was 7.4% in the DES 
group excluding BVS and 11.3% in the BMS group. In the 
DES excluding BVS group, the MACCE rate remained 
nearly stable over time, despite the extended utilisation in 
elder patients and despite the increase of complex proce-
dures. Considering this, the slight increase in mortality 
is hardly surprising, especially as some patients who 
would have been candidates for CABG surgery in earlier 
days (eg, patients with left main CAD) are increasingly 
treated with PCI. The decreasing proportion of AMI can 
be explained by the progress of DES development and 
the use of modern antiplatelet agents like Prasugrel and 
Ticagrelor.15 The proportion of coronary angiographies 
during the 1-year follow-up decreased markedly over 
time. This could be explained by an increasing percep-
tion of DES as a safe and routinely used treatment option.
Our finding of a distinctly increased 1-year MACCE 
rate in the BMS group as compared with the DES group 
has to be discussed considering the higher proportion of 
patients with an age over 70 years and with comorbidities 
in the DES group. One-year mortality in the BMS group 
was twice as high, and the proportion of AMI was higher 
by a third than in the DES group excluding BVS. In total, 
the proportion of MACCE in the BMS group increased 
significantly over the observed time frame.
The adjusted OR for the DES group excluding BVS 
as compared with the BMS group for 1-year MACCE 
was 0.72 (95% CI 0.70 to 0.75). Because the practices 
of German cardiologists have evolved during the study 
period, we included the year of PCI treatment as a 
possible confounder in the multivariable regression anal-
ysis. However, it has to be considered that DES treatment 
is not suitable for all patients and that the probability 
of ISR is higher in the rest of patients’ for whom DES 
treatment is not suitable. Clinical trials recently showed 
similar risks for DES and BMS in patients with ST-segment 
elevation myocardial infarction with respect to mortality 
and repeat AMI but advantages of DES with respect to 
repeat revascularisation.32 33 A Canadian registry study, on 
the other hand, reported a reduced 3-year mortality of 
the DES group in 2007.6
Finally, DES technology has improved over recent 
years.25 34 With new developments and increased safety, 
further patient groups will benefit from this treatment.
Conclusions
In summary, our analyses show that DES treatment 
evolved into the current standard of care over a 7-year 
observation period. Despite the increased utilisation of 
DES, 1-year MACCEs are consistently less frequent than 
group.bmj.com on November 23, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Jeschke E, et al. BMJ Open 2017;7:e017460. doi:10.1136/bmjopen-2017-017460
Open Access
with BMS over the whole observation period, with a small 
increase in the last 2 years, indicating broader use. The 
frequency of repeat coronary diagnostics and procedures 
decreased over time as DESs are increasingly perceived 
as safe. BVSs are used in clinical routine in selected cases 
with high safety, but with a high repeat-coronary angiog-
raphy rate.
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